Company: PTPI
Filing Date: 2025-01-24
Form Type: 8-K
Source: 0001104659-25-005980
Chunk: 1

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: 8-K
Item: Item 1.01
Chunk 1
---
) amend the restrictive covenant relating to the change in nature of the
Company’s business, such that such covenant does not apply to the Company’s change in sales strategy related to the
Company’s Stendra avanafil and product development strategy as it relates to the development and commercialization of a
proprietary platform focused on prescription medication to over-the-counter switch solutions. The Certificate of Amendment was filed
with the Secretary of State, effective as of January 24, 2025.

The foregoing descriptions of the Amendment Agreement
and the Certificate of Amendment are qualified in their entirety by reference to the full text of each such document, copies of which
are filed as Exhibit 10.1 and Exhibit 3.1, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

Item 3.03 Material Modification to Rights of
Security Holders.